Dual-modality, fluorescent, PLGA encapsulated bismuth nanoparticles for molecular and cellular fluorescence imaging and computed tomography by Swy, Eric R et al.
 
 
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dual-modality, fluorescent, PLGA encapsulated bismuth
nanoparticles for molecular and cellular fluorescence imaging
and computed tomography
Citation for published version:
Swy, ER, Schwartz-Duval, AS, Shuboni, DD, Latourette, MT, Mallet, CL, Parys, M, Cormode, DP & Shapiro,
EM 2014, 'Dual-modality, fluorescent, PLGA encapsulated bismuth nanoparticles for molecular and cellular
fluorescence imaging and computed tomography', Nanoscale, vol. 6, no. 21, pp. 13104-12.
https://doi.org/10.1039/c4nr01405g
Digital Object Identifier (DOI):
10.1039/c4nr01405g
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Peer reviewed version
Published In:
Nanoscale
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 06. Nov. 2020
 
 
 
 
 
 
Dual-modality, fluorescent, PLGA encapsulated bismuth 
nanoparticles for molecular and cellular fluorescence 
imaging and computed tomography 
 
 
Journal: Nanoscale 
Manuscript ID: NR-ART-03-2014-001405.R1 
Article Type: Paper 
Date Submitted by the Author: 06-Aug-2014 
Complete List of Authors: Swy, Eric; Michigan State University, Department of Radiology 
Schwartz-Duval, Aaron; Michigan State University, Department of 
Radiology 
Shuboni, Dorela; Michigan State University, Department of Radiology 
Latourette, Matt; Michigan State University, Department of Radiology 
Mallett, Christiane; Michigan State University, Department of Radiology 
Parys, Maciej; Michigan State University, Comparative Medicine and 
Integrative Biology Program 
Cormode, David; University of Pennsylvania, Radiology 
Shapiro, Erik M.; Michigan State University, Department of Radiology 
  
 
 
Nanoscale
 1
Dual-modality, fluorescent, PLGA encapsulated 
bismuth nanoparticles for molecular and cellular 
fluorescence imaging and computed tomography  
Eric R. Swy 
1*
, Aaron S. Schwartz-Duval 
1*
, Dorela D. Shuboni 
1
, Matthew T. Latourette 
1
, 
Christiane L. Mallet 
1
, Maciej Parys 
4, 5
, David P. Cormode 
6, 7, 8
 & Erik M. Shapiro 
1, 2, 3
 
#
 
1
Departments of Radiology, 
2
Physiology, 
3
Chemical Engineering, 
4
Department of Small Animal 
Clinical Sciences and 
5
Comparative Medicine and Integrative Biology Program, Michigan State 
University, East Lansing, MI 48824; Departments of 
6
Radiology, 
7
Cardiology and 
8
Bioengineering, University of Pennsylvania, Philadelphia, PA 19104 
* Denotes equal first-author contribution 
 
# Corresponding author  
Erik M. Shapiro, PhD 
Department of Radiology 
Michigan State University 
846 Service Rd 
East Lansing, MI 48824 
Tel: +1 (517)884-3270; Fax: +1 (517) 432-2849 
Email: erik.shapiro@rad.msu.edu  
Word count: ~4500  Figures:  9    Supplemental Figures: 2 
Page 1 of 34 Nanoscale
 2
ABSTRACT 
Reports of molecular and cellular imaging using computed tomography (CT) are rapidly 
increasing. Many of these reports use gold nanoparticles. Bismuth has similar CT contrast 
properties to gold while being approximately 1000-fold less expensive. Herein we report the 
design, fabrication, characterization, and CT and fluorescence imaging properties of a novel, 
dual modality, fluorescent, polymer encapsulated bismuth nanoparticle construct for computed 
tomography and fluorescence imaging. We also report on cellular internalization and preliminary 
in vitro and in vivo toxicity effects of these constructs. 40 nm bismuth(0) nanocrystals were 
synthesized and encapsulated within 120 nm Poly(DL-lactic-co-glycolic acid) (PLGA) 
nanoparticles by oil-in-water emulsion methodologies. Coumarin-6 was co-encapsulated to 
impart fluorescence. High encapsulation efficiency was achieved ~ 70% bismuth w/w. Particles 
were shown to internalize within cells following incubation in culture. Bismuth nanocrystals and 
PLGA encapsulated bismuth nanoparticles exhibited  >90% and >70% degradation, respectively, 
within 24 hours in acidic, lysosomal environment mimicking media and both remained nearly 
100% stable in cytosolic/extracellular fluid mimicking media. µCT and clinical CT imaging was 
performed at multiple X-ray tube voltages to measure concentration dependent attenuation rates 
as well as to establish the ability to detect the nanoparticles in an ex vivo biological sample. Dual 
fluorescence and CT imaging is demonstrated as well. In vivo toxicity studies in rats revealed 
neither clinically apparent side effects nor major alterations in serum chemistry and hematology 
parameters. Calculations on minimal detection requirements for in vivo targeted imaging using 
these nanoparticles are presented. Indeed, our results indicate that these nanoparticles may serve 
as a platform for sensitive and specific targeted molecular CT and fluorescence imaging.  
Page 2 of 34Nanoscale
 3
Keywords: bismuth, computed tomography, nanoparticle, fluorescence imaging, Poly(DL-lactic-
co-glycolic acid)  
Page 3 of 34 Nanoscale
 4
INTRODUCTION 
High atomic number (Z) metal nanocrystals are recognized for their potential to move 
computed tomography (CT) from a mostly structural imaging paradigm into a molecular imaging 
modality
1-4
, particularly if coupled with emerging spectral CT methodologies
5-8
. The field is 
reviewed in Cormode, et al
9
. Gold nanoparticles (Z = 79, k-edge = 80.7 keV) are the most well 
developed nanoparticle platform, however the cost of gold may be prohibitive for widespread 
use. Bismuth nanoparticles (Z = 83, k-edge = 90.5 keV) are a cost effective alternative with 
potentially equal CT contrast/biocompatibility to gold. Further, bismuth compounds are 
biodegradable and biocompatible with a long history in biomedicine. 
To date, most investigations centering on the use of bismuth for nanoparticulate CT 
agents have used Bi2S3 as the payload, formulating hydrophilic nanoparticles by using 
surfactant-based coatings
10, 11
. While excellent size control of nanocrystals has recently been 
reported
12
, one disadvantage of Bi2S3 is the reduction in the mass percent of bismuth in the 
formula unit to 80%. Furthermore, the density of Bi2S3 is 6.78 g/ml while that of pure bismuth is 
9.78 g/ml, a 31% decrease. Combining these two percentages (80% x 69%) yields 55% decrease 
in the concentration of bismuth in Bi2S3 versus elemental bismuth. An alternative formulation 
has incorporated organometallic bismuth neodecanoate complexes into nanoemulsions, again 
resulting in a relatively low bismuth loading density
13
. A third nanoparticle formulation has 
incorporated ~ 20 nm elemental bismuth nanocrystals within 130 nm dextran particles
14
. This 
packing is similar to ferumoxides, an iron oxide nanoparticle for MRI, and inefficiently packages 
bismuth by volume, with the bismuth payload forming only 0.3% of the total volume. 
CT suffers from inherently poor sensitivity, with minimal detection concentrations in the 
millimolar range
15
. As such, to facilitate molecular and cellular CT, a premium must be placed 
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on efficient delivery and packaging of CT dense contrast material. Herein we describe the 
design, synthesis, characterization, and ex vivo CT and fluorescence imaging of novel 
fluorescent, Poly(DL-lactic-co-glycolic acid) (PLGA) encapsulated bismuth nanoparticles for 
dual CT/fluorescence applications. These particles build on previously reported technology that 
has been used to form PLGA encapsulated iron oxide
16, 17
, manganese oxide
18
 and gadolinium 
oxide nanoparticles
19
. This platform has been shown to incorporate high payloads of inorganic 
nanocrystals via a facile oil-in-water emulsion approach. The major innovations in the use of 
bismuth-based CT nanoparticles are: 1) the use of elemental bismuth nanocrystals for higher 
contrast density, rather than Bi2S3, 2) the encapsulation of nanocrystals within an FDA approved 
polymer, 3) very simple and scalable encapsulation process, and 4) high encapsulation 
efficiency, resulting in high weight percent of internalized bismuth. 
 
MATERIALS AND METHODS
 
Bismuth Nanocrystal Synthesis 
Bismuth nanocrystals were synthesized according to Son, et al
12
. Briefly, 3.6 grams (5 
mmol) of bismuth neodecanoate (Sigma-Aldrich St. Louis, MO, USA) was combined with 25 
mL of 1-octadecene (Sigma-Aldrich St. Louis, MO, USA).  The mixture was then heated to 120 
º
C under a N2 atmosphere for 2 hours to remove water and dissolved oxygen. The mixture was 
then cooled to 80 
º
C with continuous stirring. 1.2 mL of 1-dodecanethiol (DDT) (Sigma-Aldrich 
St.  Louis, MO, USA) was then added and the mixture was kept at 80 
º
C for 5 minutes.  The 
addition of DDT caused the solution to change from colorless to yellow, indicating the formation 
of the bismuth dodecanethiolate complex.  Next, 5 mL of tri-octylphosphine (Alfa Aesar, 
Heysham, England) was injected, causing the yellow solution to turn black.  The reaction was 
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then cooled and maintained at its growing temperature of 60 
º
C for 30 minutes with continuous 
stirring. The nanocrystals formed were then precipitated with a 10:1 (v/v) mixture of 
acetone/tetrahydrofuran (THF), and retrieved by centrifugation (17,000 g x 10 minutes) and 
washed several times with 10:1 (v/v) acetone/THF.   
Bismuth Nanocrystal Characterization 
 X-ray diffraction patterns (D8 Advance diffractometer, Bruker Corporation, Billerica, 
MA) were matched with library of diffraction patterns to determine molecular identity as 
bismuth(0)
12, 20
. Fourier transform infrared spectroscopy (FTIR) was performed on a Mattson 
Genesis 3025 FTIR spectrometer to verify that DDT was present on the bismuth nanocrystals. 
Nanocrystals were imaged with transmission electron microscopy (TEM) using a 
JEOL 2200FS Transmission Electron Microscope (JEOL Ltd, Tokyo, Japan). Nanocrystal size 
(average +/- SD) was determined by ImageJ (http://rsbweb.nih.gov/ij/) analysis of TEM images. 
Nanocrystal Encapsulation in PLGA nanoparticles 
Prior to encapsulation, bismuth nanocrystals were incubated at room temperature in oleic 
acid for 24 hours (1 mL oleic acid per 200 mg bismuth). Nanocrystals were then washed twice 
with 2 ml ethanol to remove excess oleic acid.   
The PLGA encapsulation method was based on that reported by Granot, et al
16
. A stock 
solution of Poly(DL-lactic-co-glycolic acid) (PLGA) was made by dissolving 1 gram of PLGA 
in 20 mL dichloromethane (DCM) overnight. Separate solutions of 5% (5 g in 100 mL) and 0.3% 
(0.3 g in 100 mL) polyvinyl alcohol (PVA) in deionized water were prepared.   
To fabricate particles, 2 mL PLGA polymer solution was first placed in a small test tube. 
Between 10-200 mg of nanocrystals were then added along with 500 µL of a 2 mg/mL DCM 
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solution of coumarin-6 to enable fluorescent labeling. The mixture was then bath sonicated and 
vortexed to disperse the nanocrystals. The organic mixture was then added drop-wise to 4 mL 
5% PVA solution while vortexing at high speed. The mixture was then vortexed for an additional 
10 seconds. The test tube was then tip sonicated three times at 40% amplitude for ten seconds 
each time to create an oil-in-water emulsion. The test tube was placed in an ice bath between 
each sonication. After the third tip sonication, the tube’s contents were poured into a 60 mL 
0.3% PVA solution. The mixture was then stirred with an overhead stirrer for 3 hours to allow 
nanoparticle formation and DCM evaporation. The nanoparticles were washed 3 times with 20 
mL portions of deionized water and collected by centrifugation (17,000 g for 10 minutes). The 
nanoparticles were then re-suspended in 1 mL deionized water, flash frozen in liquid N2, and 
lyophilized.    
Nanoparticle Characterization 
 Nanoparticle formation was analyzed and diameter was measured (average +/- SD) by 
scanning electron microscopy (SEM) using an AURIGA® CrossBeam Dual Column SEM-FIB 
Workstation (Carl Zeiss, Jena, Germany). Bismuth content and encapsulation efficiency was 
determined by thermogravimetric analysis (TGA) using a Q500 TGA from TA instruments (New 
Castle, DE). TEM was performed to determine spatial localization of bismuth nanocrystals 
within the PLGA particle.  
Nanocrystal Dissolution 
The dissolution of bare bismuth nanocrystals and bismuth nanocrystals in PLGA 
nanoparticles was assessed using inductively coupled plasma optical emission spectrometry 
(Varian, 710-ES ICP-OES). To determine the rate at which bismuth dissolves into phosphate 
buffer saline (PBS) and sodium citrate, 10 mg of bismuth nanocrystals or 15 mg of particles 
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containing 66% w/w bismuth were suspended in either 1 mL of PBS or 1 mL of sodium citrate 
(pH 5.5). Microcentrifuge tubes containing the 4 mixtures were sonicated and then maintained 
on a rotary shaker at 36 °C. The tubes were centrifuged briefly to collect the supernatant sample 
and the remaining pellet was then resuspended in fresh solution prior to being returned to the 
oven. Supernatant was collected from samples at 1, 4, 9, 18, and 24 hrs on the first day, every 24 
hrs for 2 weeks, and subsequently every week for the remainder of the experiment. After the 
supernatant for all the desired time points had been collected, all the samples were dried using a 
heating block and then 1 mL of concentrated nitric acid (69% HNO3) was added to each dried 
sample. After 48 hrs, samples were diluted with ultrapure water to a final concentration of 2% 
HNO3 and then each sample was analyzed in triplicate using ICP-OES. 
Cell Labeling and In Vitro Toxicity 
For all in vitro assays, STO mouse fibroblasts (ATCC) were maintained in Dulbecco’s 
modified Eagle medium (DMEM) supplemented with 10% fetal bovine serum at 37ºC and 5% 
CO2. All cell culture materials are from Life Technologies. 
For the cell proliferation assay, STO cells were plated at 100,000 per well in a 24-well 
plate and allowed to adhere overnight. PLGA encapsulated bismuth nanoparticles were 
suspended in media at 1 mg Bi/mL, sonicated, and 10-fold dilutions in media were made down to 
0.1 µg/mL. 500 µL of nanoparticle solution was added to each well. Controls received fresh 
media only. After 2 days of co-incubation, the nanoparticle solution was removed and replaced 
with a mixture of 400 µL media and 40 µL of MTT powder (1-(4,5-Dimethylthiazol-2-yl)-3,5-
diphenylformazan, Sigma) at 5 mg/mL in PBS. 2 hours later, the media was aspirated and 1 mL 
of dimethylsulfoxide (DMSO, Fisher) was added to each well. 50 µL was immediately 
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transferred to a 96-well plate and absorbance was measured at 560 nm using a plate reader 
(SpectraMax 190, Molecular Devices). The absorbance of DMSO-only wells was used to 
establish a baseline. For each experiment, 3 wells were tested per concentration of bismuth, and 
the experiment was repeated twice. The optical density measurements were normalized to that of 
the wells containing cells that were not exposed to the PLGA encapsulated bismuth 
nanoparticles. 
To measure apoptosis and cell viability after incubation with PLGA encapsulated 
bismuth nanoparticles, a flow cytometry assay was used (Pacific Blue annexin V apoptosis 
detection kit with 7-AAD, BioLegend). STO cells were plated and allowed to adhere overnight. 
The next day, PLGA encapsulated bismuth nanoparticles were suspended in PBS containing 
0.01% poly-L-lysine (PLL) (poly-L-lysine hydrobromide, Sigma), bath sonicated, then added to 
the cells at 5, 50 or 150 pg/cell for 24 hours. Cells were harvested by trypsinization and stained 
with annexin V and 7AAD according to the manufacturer’s protocol. Cell samples were analyzed 
on a BD LSR II flow cytometer using FACSDiva software (Becton Dickson). Results were 
visualized using FlowJo vX software (TreeStar). 
For the TEM, cells were plated and allowed to adhere overnight. PLGA encapsulated 
bismuth nanoparticles were suspended in PBS containing 0.01% PLL and added to the cells at 25 
and 200 pg/cell for 24 hours. The cells were harvested by trypsinization and washed thrice in 
HBSS, then fixed in a mixture of 2.5% glutaraldehyde + 2.5 % paraformaldehyde in 0.1 M 
cacodylate buffer at 4°C for 24 hours, postfixed in 1% osmium tetroxide and dehydrated in a 
graded acetone series. Samples were infiltrated and embedded in Spurr resin (Polysciences). 
Thin sections (70 nm) were obtained with a PTXL ultramicrotome (RMC, Boeckeler 
Instruments, Tucson, AZ) on 200 mesh copper grids stained with uranyl acetate and lead citrate.  
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Sections were imaged using a JEOL 100CX Transmission Electron Microscope at a 100kV 
accelerating voltage.  
In Vivo Toxicity 
18 male Sprague-Dawley rats, weighing approximately 250-300g each, were acclimated 
to the laboratory environment for at least 1 week, then injected IV or IP with PLGA encapsulated 
bismuth nanoparticles at 0, 2 or 20 mg Bi/kg of Bi NP (6 groups, 3 rats per group) at a volume of 
5 ml/kg. Animals were anesthetized with isoflurane at 24 hours post-dosing and again on Study 
Day 8 for blood collection. Blood was collected into EDTA and serum tubes for biochemistry 
and hematology panels. Following the final blood collection on Day 8, all animals were 
euthanized, and the kidneys, liver, lungs, and spleen were collected, weighed, and preserved in 
10% buffered formalin. One animal per group was selected for histopathological analysis and 
processed for paraffin sectioning, H&E staining and examination by a trained pathologist.  
Within group differences were assessed using a one-way ANOVA with post-hoc 
comparisons to the vehicle group (Group 1 or 2) of the same dosing route using Dunnett’s 
procedure to correct for multiple comparisons (GraphPad Prism 5.03). In cases where 
insufficient data were available for one-way ANOVA assessment, but the vehicle group and one 
or more dose groups could be analyzed, two-tailed paired or unpaired t-tests were used to 
evaluate within-group differences. Parameters are reported as group mean ±SE. In all cases, a p-
value of <0.05 was considered significant. 
In Vitro and Ex Vivo Sample Preparation for µCT and Clinical CT  
In vitro samples of PLGA encapsulated bismuth nanoparticles containing 0, 14, 46, 64, 
and 143 mM bismuth were prepared in 200µL of 0.5% agarose.  
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A 90 mM bismuth suspension was prepared using 10.2 mg PLGA encapsulated bismuth 
nanoparticles (63% w/w bismuth from TGA) in 340µL of di H2O for ex vivo imaging in chicken 
wing forearm.  Using a one mL syringe in combination with 26 gauge ½ inch needle, the 90 mM 
suspension of nanoparticles was injected slowly over the course of 1 minute between the radius 
and the ulna of a chicken wing forearm. After the injection was complete, the needle was 
allowed to rest in the injection site for an additional minute prior to removal.     
µCT and Clinical CT  
In vitro and ex vivo imaging was performed using both µCT and clinical CT scanners, 
guided using parameters described by Galper, et al
15
.  µCT scans were performed on a GE 
eXplore Locus µCT Scanner (GE, Waukesha, Wisconsin) with a tube voltage of 80 kV and 450 
µA, while clinical CT scans were performed on a GE Discovery 750 HD CT scanner (GE, 
Waukesha, Wisconsin) with tube voltages of 80, 100, 120, and 140 kV and 100 mA. Regions of 
interest were drawn within areas of contrast following calibration to Hounsfield units. 
Ex Vivo Fluorescent Imaging and µCT 
~50 µg of PLGA encapsulated bismuth fluorescence particles was delivered into chicken 
meat. Ex vivo fluorescent imaging was performed with IVIS Spectrum (Perkin Elmer, Waltham, 
MA) using a 430 nm excitation filter, 530 nm emission filter and automatic exposure and f stop 
settings. µCT scans were performed as above. 
 
RESULTS 
Bismuth(0) nanocrystals were synthesized by reduction of bismuth dodecanthiolate
12
.   
The average nanocrystal diameter as determined by TEM was 38.0 ± 7.1 nm (Figure 1A). We 
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found that temperature control was the single most important parameter in maintaining uniform 
crystal size as reported in Son, et al
12
. XRD confirmed that the nanocrystals were composed of 
elemental bismuth (Figure 1A), as opposed to a bismuth salt.  FTIR confirmed that dodecanethiol 
(DDT) coated the nanocrystals by the presence of peaks at wavenumbers of 2831 and 2919 cm
-1
 
(Figure 1B).   
Bismuth nanocrystals and coumarin-6 were co-encapsulated into PLGA nanoparticles by 
a simple oil-in-water emulsion approach, as shown schematically in Figure 2. The formation of 
PLGA nanoparticles was confirmed by SEM (Figure 3A) and the nanoparticles were determined 
to have an average diameter of 120.4 ± 37.0 nm. TEM confirmed that bismuth nanocrystals were 
encapsulated within the core of the PLGA nanoparticles, rather than at or near the surface 
(Figure 3B). Different nanoparticle formulations were determined to contain ~ 60-80% w/w 
bismuth by TGA analysis, with Figure 4 showing a thermogram for a sample with 78.0 ± 6.9% 
bismuth w/w. Initial experiments found that DDT coated bismuth nanocrystals did not 
incorporate at all within PLGA without preincubation in oleic acid. FTIR analysis (data not 
shown) indicates that oleic acid does not adsorb to the surface of the nanocrystal, as the sharp 
carbonyl peak of the acid group remains following washing with ethanol. Adsorption would 
result in the disappearance of this carbonyl peak and the appearance of two C-O-O stretches. In 
this synthetic approach, we hypothesize that oleic acid acts as a surfactant. The requirement of an 
excipient for successful encapsulation of bismuth is similar to Mieszawska, et al
21
, where 
elemental gold nanocrystals coated with DDT were challenging to incorporate within PLGA. In 
that case, they used a covalent binding strategy to overcome the issue. Fluorescence spectra 
indicate no spectral shift in the wavelength of coumarin-6 following incorporation into 
nanoparticles. 
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As expected, following incubation of STO fibroblasts with particles in culture, particles 
were internalized into endo/lysosomes. Figure 5 shows TEM of control cells (Figure 5A) and 
labeled cells (Figure 5B-F), with Figure 5B&C showing labeling from 25 pg Bi/cell labeling 
condition and Figure 5D-F showing labeling from 200 pg Bi/cell labeling condition. In labeled 
cells, black nanocrystals can be seen within fluid-filled endo/lysosomal compartments with the 
number of labeled compartments increasing with labeling dose. 
The dissolution of bismuth nanocrystals, both as bare nanocrystals and encapsulated in 
PLGA, was studied in solvents representing physiological relevant conditions in vitro. 
Specifically, incubation in sodium citrate mimics the post-endocytosis environment of a 
lysosome with a low pH and the presence of citrate 
22, 23
. PBS mimics cytosolic and extracellular 
pH. As previously reported for PLGA encapsulated iron oxide nanoparticles, the bismuth 
particles had a similar initial “burst” pattern of dissolution
17
. However, the rate of the dissolution 
was faster for PLGA encapsulated bismuth nanoparticles than for iron particles, consuming 
almost 70% of the bismuth nanocrystals in 24 hr (Figure 6). The rate of the initial burst phase 
was even greater in the bare 38 nm bismuth nanocrystals samples, reaching 90% of the bismuth 
dissolved within the first 24 hrs (Figure 6). In stark contrast, neither the bismuth nanocrystals nor 
nanocrystal loaded nanoparticles degraded in the PBS solution. At the completion of the 
experiment only 0.7% of the crystals and 0.2% of the particles had dissolved into the solution, 
indicating that both are relatively stable in the neutral environment representative of the 
extracellular environment of a cell
17
. 
 To measure the rate of attenuation of PLGA encapsulated bismuth nanoparticles, µCT 
and clinical CT imaging was performed on vials containing 0, 14, 46, 64, and 143 mM 
concentrations of bismuth (Figure 7A). For µCT, a linear relationship between attenuation and 
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bismuth concentration (R
2
=0.98) was revealed with a slope or rate of attenuation of 10.2 HU/mM 
(Figure 7B). In vitro clinical CT of these same vials at 80, 100, 120, and 140kV (Figure 7A) 
were similarly linear and had rates of attenuation of 6.6, 5.9, 5.3 and 5.1 HU/mM, respectively 
(Figure 7B), similar to that previously determined for gold
15
. The discrepancy in rates of 
attenuation between the pre-clinical and clinical systems, due to the µCT having a greater low 
energy component of its X-ray beam than the clinical CT, highlights the importance of 
evaluating new CT materials on clinical systems. Further, this also suggests that preclinical use 
of CT agents may afford more sensitive investigations than clinical projects, opening the door for 
the expanded use of preclinical µCT in basic biology as is common with MRI.  
To demonstrate µCT and clinical CT detection PLGA encapsulated bismuth 
nanoparticles, particles were injected into a chicken wing. Ex vivo CT imaging of the chicken 
wing with both µCT and clinical CT at 80 kV (Figure 8) detected nanoparticles as hypointense 
signal, measured to be 2435 ± 44 HU on the µCT and 1344 ± 178 HU on the clinical CT. Using 
the calculated HU/mM for Bi at 80 kVp as determined in Figure 7 yields Bi concentrations of 
238 and 204 mM, respectively, statistically insignificant with respect to each other. These values 
are more than double the concentration of bismuth delivered, 90 mM, and likely reflect 
precipitation or aggregation of the injected nanoparticles following injection within the tissue. 
This data proved that the nanoparticles retain their contrast generating properties after injection 
into tissue. However, this result encouragingly points towards the potential of significant 
accumulations of contrast agent occurring in a tumor or within an atherosclerotic plaque by EPR 
effect or by targeted delivery. In Figure 9 we present side by side CT and fluorescence images of 
a tissue sample injected with the nanoparticles. As can be seen, there is excellent co-localization 
of the fluorescence and CT signal, demonstrating the bimodal imaging functionality of the agent.  
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 MTT assays were performed on cells labeled with particles in vitro. After a one-way 
ANOVA found that there was a significant effect of bismuth concentration on cell proliferation 
(p=0.0001), t-tests were performed to determine which values were significantly different from 
the controls. At 0.0001 mg/mL, 0.001 mg/mL and 0.01 mg/mL, there was no statistically 
significant effect on proliferation. At the highest concentrations (0.1 mg/mL and 1 mg/mL), there 
was significantly less cell proliferation than in the controls (Sup Figure 1).  
Flow cytometry was used to measure cells that were either apoptotic and/or dead. Flow 
cytometry assays for annexin V and 7AAD found that the control cells were 10% double-
positive. Low levels of labeling did not affect cell viability but higher concentrations of bismuth 
reduced viability. Cells that were incubated with 5 pg/cell of bismuth were 24% double positive, 
while cells exposed to 150 pg/cell were 36% double positive (Sup Figure 2).  
A rigorous in vivo toxicity study was also performed. The full results are detailed in 
Supplemental Data. No animals showed any apparent clinical abnormalities, aside from loose 
stools in a few animals at 24 hours post injection (both IV injected experimental groups) and at 
day 8 (control group, IP injection).   
Some serum chemistry values were altered at both 24 hours and 7 days post-injection. 
These alterations were most significantly noted in those animals that received IV administration 
of the nanoparticles, although some were also noted in the high dose IP injected animals. As 
expected, these changes are within the pathways for kidney and liver metabolism. Notably, 
elevation in liver enzymes at 24 hours post injection of particles was fully resolved at 7 days. 
Hematology was also examined. At 24-hours post-injection, and at 7 day time point, 
mean platelet volume (MPV) was statistically increased in the group of animals receiving 
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20mg/kg IV. The same group had a statistically significant reduction in hematocrit and 
hemoglobin, with increased white blood cell and lymphocyte counts. 
A pathological and histopathological evaluation was performed on one animal from each 
group. No statistically significant changes in organ weights were noted and no gross changes 
were identified on necropsy. Mild to moderate BALT hyperplasia was a common finding in 
nearly every animal, possibly due to mycoplasma infection. In one animal from high dose IV 
injection, focal regions of alveolar macrophages within alveoli were identified. Occasional 
pathological findings were observed in spleen, kidney and liver. Of note, one animal from the 
high dose IV injection showed evidence of regeneration of the kidney following transient injury.  
 
DISCUSSION 
In this manuscript we report on the design, fabrication, characterization and extensive in 
vitro and in vivo assaying of PLGA encapsulated bismuth nanoparticles, which can be utilized as 
a potential CT contrast agent. The synthetic approach is facile and flexible, permitting one to 
tailor the approach for encapsulating less bismuth if desired, changing the overall size of the 
particle and using other hydrophobic polymers for encapsulation.  
The toxicological aspects of bismuth preparations are well established and the published 
side effects of various routes of injection include nephropathy, hepatitis, encephalopathy, 
gastroenteritis and osteoarthropathy
24-30
. In this study, although no clinically apparent side 
effects were noted, several changes were identified on clinicopathological and histopathological 
evaluation of animals and their internal organs. The group with the most apparent changes was 
the high dose, 20mg/kg IV group. Histopathological changes in this group included ones 
suggestive of transient kidney injury and periportal inflammatory process in the liver. These 
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changes correlate with the routes of bismuth excretion from the body
27, 28
. Previous studies have 
shown that after IV injection of various bismuth preparations the majority of bismuth 
concentrates in the kidneys
27, 31
. Studies have previously described reversible kidney failure after 
ingestion of bismuth and characteristic histopathological changes
24, 32
. In this study, 
characteristic kidney injury affecting tubular epithelial cells was noted in an animal from the 
20mg/kg IV group. Regarding clinicopathologic values that may suggest kidney injury, only 
magnesium levels were significantly lower in this group. Significant reduction of hematocrit may 
be a result of kidney injury, although eryptosis – an apoptotic death of erythrocytes, is more 
likely. Bismuth has recently been described as a potential trigger of eryptosis 
33
. This metal 
induces cellular multiple changes characteristic for this process – phosphatydylserine expression 
on cell surface, decrease in erythrocyte size, increase in intracellular Ca
2+
 activity and formation 
of ceramide leading to erythrocyte death
33
.  
 Another route of excretion of this heavy metal is via bile, and rarely, liver injury has also 
been reported after bismuth ingestion
27, 31
. Periportal inflammatory cell infiltrates in the liver 
were apparent in the 20mg/kg IV group and early (24 hours post particle injection) increase in 
liver enzymes was significant in this group. Decrease in hemoglobin concentration may be also 
associated with liver toxicity due to bismuth and how it affects the liver cells and their 
mitochondria. Concurrent lymphocyte and total white blood cell count increases, and 
subsequently an increase in globulin and total protein levels, are suggesting an inflammatory 
response that is probably triggered by bismuth injection. 
As mentioned earlier, CT imaging suffers from low sensitivity, with contrast agent 
concentration requirements currently being in the millimolar range. However, the dense 
encapsulation of contrast agents like elemental bismuth within nanoparticles can overcome a 
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seemingly difficult barrier to detection. Take for example a cancer targeting paradigm, where 
one strives to achieve a very high 100 mM bismuth concentration targeted to a tumor. Elemental 
bismuth has a molecular weight of ~ 200 g/mol and density ~ 10g/ml. A 40 nm bismuth spherical 
nanocrystal has a volume of 3.2 x 10
-20
 L and weighs 3.2 x 10
-16
 g. Cubic nanocrystals would 
have double the volume and mass. In this example we assume the use of 1 mm isotropic pixels in 
a clinical CT scan. To achieve 100 mM bismuth, one would require 3.0 x 10
6
 spherical or 1.5 x 
10
6
 cubic nanocrystals in that pixel. Assuming in this tumor model that there are ~ 10
6
-10
7
 tumor 
cells per mm
3
, one would need to target 3-30 PLGA-encapsulated single bismuth spherical 
nanocrystals to each cell in this tumor to achieve 100 mM concentration. Given that targetable 
cell surface antigens are in the range of 10
4
-10
5
, this becomes a solvable challenge. Were one to 
accomplish encapsulation of multiple nanocrystals within single particles, as Figure 2 shows is 
possible, this becomes an even easier problem to solve, with requirements ~ single particles/cell 
for 100 mM detection. 
 
Conclusions 
 In summary, degradable, elemental bismuth nanocrystals have been efficiently 
encapsulated within 120 nm PLGA nanoparticles. As PLGA is an FDA approved polymer, these 
particles have an advantage for long term clinical potential, though mild, transient toxicity from 
bismuth was identified in preliminary in vitro and in vivo assays. Further refinements to this 
system depend on proposed use. Toxicity can likely be reduced by tailoring the dissolution rate 
of the bismuth as has been achieved with manganese based particles
34
. For cell tracking, simple 
incubation of particles with cells results in high internalization, similar to what has been 
accomplished with previous metal oxide nanoparticles
16-19, 35
. For passive targeting of 
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compromised vascularity due to injury or disease, cryoprotection
35
 and PEG coating
36
 would 
likely be necessary. Active targeting would necessitate a careful balance between PEG and 
targeting ligand
36
. Lastly, paradigms such as described here, where multiple nanocrystal cores 
are encapsulated in polymer nanoparticles may enable molecular and cellular CT as it addresses 
the well-accepted concentration challenge associated with CT contrast agents. 
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Figure legends 
 
Figure 1: (A) XRD analysis of bismuth nanocrystal product. Inset: TEM image of bismuth 
nanocrystals. Average diameter: 38.0 ± 7.1 nm. Scale bar is 50 nm. (B) FTIR analysis of bismuth 
nanocrystals and a reference sample of DDT.  Inset: expansion of peaks at wavenumbers of 2919 
and 2831 cm
-1
. 
 
Figure 2: Schematic illustration of fabrication scheme for fluorescent, PLGA encapsulated 
bismuth nanocrystals. Coumarin and bismuth nanocrystals, along with PLGA, are dissolved in 
dichloromethane. This oil phase is added to the aqueous phase, comprised of 5% PVA. An oil-in-
water emulsion is formed by tip sonication. Mechanical stirring for three hours allows 
dichloromethane to evaporate, generating hardened PLGA nanoparticles encapsulating both 
coumarin and bismuth nanocrystals. 
 
 Figure 3: (A) SEM image of bismuth containing nanoparticles with average size of 120.4 ± 37.0 
nm. Scale bar is 1 micron. (B) Bismuth nanoparticle diameter distribution. Inset: TEM images of 
bismuth nanocrystal containing nanoparticles. Scale bar is 100 nm. 
 
Figure 4: Averaged thermograms with standard deviations for bismuth nanocrystal containing 
PLGA nanoparticles (n=4). Bismuth content of the nanoparticles was determined to be 78% w/w. 
 
Page 20 of 34Nanoscale
 21
Figure 5: Transmission electron microscopy of A) unlabeled cell, B&C) cell labeled with 25 pg 
Bi/cell, D-F) cell labeled with 200 pg Bi/cell. C is a rotated zoom of boxed region in B. E is an 
zoom of boxed region in D. F is a rotated zoom of boxed region in E. Still intact PLGA 
encapsulated bismuth nanoparticles can potentially be seen in the endo/lysosome in F.  
 
Figure 6: Bismuth release from unencapsulated bismuth nanocrystals and PLGA encapsulated 
bismuth nanoparticles in PBS and sodium citrate over 42 days. Inset: Expansion of the results 
over the first 48 hrs. 
 
Figure 7: (A) Clinical CT image and (B) µCT image of vials containing bismuth nanoparticles 
labeled 1-5 with bismuth concentrations of 0, 14, 46, 64, and 143 mM, respectively. (C) Graph of 
attenuation vs. concentration of bismuth at different X-ray tube voltages. Clinical CT kVp values 
of 80, 100, 120, and 140kVp and µCT value of 80kV. 
 
Figure 8: (A) µCT image of chicken forearm prior to bismuth nanoparticle injection. (B) µCT 
image of the same slice, post bismuth nanoparticle injection. (C) Clinical CT image of the same 
slice, post bismuth nanoparticle injection. Arrow indicates the site of injection. 
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Figure 9: (A) Volume rendering from µCT image of chicken thigh meat injected with 
fluorescent, PLGA encapsulated bismuth nanoparticles. Scale bar is 1 cm. (B) Fluorescent image 
of the same. Fluorescence units are radiant efficiency (
p/sec/cm2/sr
μW/cm2
). 
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Figure 1: (A) XRD analysis of bismuth nanocrystal product. Inset: TEM image of bismuth nanocrystals. 
Average diameter: 38.0 ± 7.1 nm. Scale bar is 50 nm. (B) FTIR analysis of bismuth nanocrystals and a 
reference sample of DDT.  Inset: expansion of peaks at wavenumbers of 2919 and 2831 cm-1.  
127x181mm (300 x 300 DPI)  
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Figure 2: Schematic illustration of fabrication scheme for fluorescent, PLGA encapsulated bismuth 
nanocrystals. Coumarin and bismuth nanocrystals, along with PLGA, are dissolved in dichloromethane. This 
oil phase is added to the aqueous phase, comprised of 5% PVA. An oil-in-water emulsion is formed by tip 
sonication. Mechanical stirring for three hours allows dichloromethane to evaporate, generating hardened 
PLGA nanoparticles encapsulating both coumarin and bismuth nanocrystals.  
45x15mm (300 x 300 DPI)  
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Figure 3: (A) SEM image of bismuth containing nanoparticles with average size of 120.4 ± 37.0 nm. Scale 
bar is 1 micron. (B) Bismuth nanoparticle diameter distribution. Inset: TEM images of bismuth nanocrystal 
containing nanoparticles. Scale bar is 100 nm.  
61x30mm (300 x 300 DPI)  
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Figure 4: Averaged thermograms with standard deviations for bismuth nanocrystal containing PLGA 
nanoparticles (n=4). Bismuth content of the nanoparticles was determined to be 78% w/w.  
77x59mm (300 x 300 DPI)  
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Figure 5: Transmission electron microscopy of A) unlabeled cell, B&C) cell labeled with 25 pg Bi/cell, D-F) 
cell labeled with 200 pg Bi/cell. C is a rotated zoom of boxed region in B. E is an zoom of boxed region in D. 
F is a rotated zoom of boxed region in E. Still intact PLGA encapsulated bismuth nanoparticles can 
potentially be seen in the endo/lysosome in F.  
52x26mm (300 x 300 DPI)  
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Figure 6: Bismuth release from unencapsulated bismuth nanocrystals and PLGA encapsulated bismuth 
nanoparticles in PBS and sodium citrate over 42 days. Inset: Expansion of the results over the first 48 hrs.  
101x80mm (300 x 300 DPI)  
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Figure 7: (A) Clinical CT image and (B) µCT image of vials containing bismuth nanoparticles labeled 1-5 with 
bismuth concentrations of 0, 14, 46, 64, and 143 mM, respectively. (C) Graph of attenuation vs. 
concentration of bismuth at different X-ray tube voltages. Clinical CT kVp values of 80, 100, 120, and 
140kVp and µCT value of 80kV.  
53x27mm (600 x 600 DPI)  
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Figure 8: (A) µCT image of chicken forearm prior to bismuth nanoparticle injection. (B) µCT image of the 
same slice, post bismuth nanoparticle injection. (C) Clinical CT image of the same slice, post bismuth 
nanoparticle injection. Arrow indicates the site of injection.  
36x8mm (300 x 300 DPI)  
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Figure 9: (A) Volume rendering from µCT image of chicken thigh meat injected with fluorescent, PLGA 
encapsulated bismuth nanoparticles. Scale bar is 1 cm. (B) Fluorescent image of the same. Fluorescence 
units are radiant efficiency ((p/sec/cm^2/sr)/(µW/cm^2)).  
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